<?xml version="1.0" encoding="UTF-8"?>
<p>The Urabe Am9 strain was evaluated in children 14 to 20 months of age in a comparative trial with the Jeryl Lynn strain [
 <xref rid="B106-ijerph-17-01686" ref-type="bibr">106</xref>]. The seroconversion rates at six weeks, as detected with either one or two tests, were 94.8% after the Urabe Am9 strain and 96.7% after the Jeryl Lynn vaccine. Only mild infrequent adverse reactions were observed. Both strains of live attenuated mumps vaccine were immunogenic and well tolerated in this age group.
</p>
